Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

United States Cellular plans to sell its wireless operations and 30% of its spectrum to T-Mobile for $4.4 billion, exiting the wireless business by mid-2025. U.S. Cellular will retain 70% of its ...

In a world first, researchers at the Kennedy Institute, Oxford have mapped the cellular dynamics following treatment with the most commonly used advanced therapy in autoimmune diseases.

Previously, we could only use abemaciclib, and now we have a new ribociclib. If a patient is ... every 21 days over 1 cycle. Another benefit of this medication is we are not too worried about ...

Verizon Communications Inc., the biggest wireless carrier in the US, will buy some of US Cellular Corp.’s spectrum licenses for $1 billion as the tower operator sheds parts of its portfolio.

Oct 18 (Reuters) - United States Cellular (USM.N), opens new tab said on Friday it has agreed to sell some of its spectrum licenses to Verizon (VZ.N), opens new tab in a $1 billion deal.

U.S. Cellular agreed to sell part of its spectrum licenses to Verizon for $1.0 billion in cash, pending regulatory approval. Additional agreements with two mobile operators to sell more spectrum ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...